{"id":11351,"date":"2025-08-22T16:07:37","date_gmt":"2025-08-22T11:07:37","guid":{"rendered":"https:\/\/ksestocks.com\/blog\/?p=11351"},"modified":"2025-08-22T16:07:39","modified_gmt":"2025-08-22T11:07:39","slug":"abbott-laboratories-pakistan-limited-abot-riding-the-pharma-growth-wave","status":"publish","type":"post","link":"https:\/\/ksestocks.com\/blog\/abbott-laboratories-pakistan-limited-abot-riding-the-pharma-growth-wave\/","title":{"rendered":"Abbott Laboratories (Pakistan) Limited (ABOT): Riding the Pharma Growth Wave"},"content":{"rendered":"\n<p><strong>Abbott Laboratories (Pakistan) Limited (<a href=\"https:\/\/ksestocks.com\/blog\/tag\/abot\/\" data-type=\"post_tag\" data-id=\"380\" target=\"_blank\" rel=\"noreferrer noopener\">ABOT<\/a>)<\/strong> has emerged as one of the standout players in the pharmaceutical sector this year. The company\u2019s performance in the April\u2013June 2025 quarter shows how changing regulations and strong product demand are fueling growth.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Big jump in earnings<\/h2>\n\n\n\n<p>ABOT is expected to post <strong>earnings of PKR 20.45 per share in 2QCY25<\/strong>, a massive <strong>221% increase year-on-year<\/strong>. In simple words, profits have more than tripled compared to the same period last year. The company\u2019s net profit is estimated at <strong>PKR 2.0 billion<\/strong> for the quarter.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What\u2019s driving growth?<\/h2>\n\n\n\n<p>Several factors are behind this impressive growth:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Higher Sales<\/strong>: Products like <strong>Brufen, Surbex, and Arinac<\/strong> saw a 5% rise in sales from the last quarter, helped by seasonal demand.<\/li>\n\n\n\n<li><strong>New Products<\/strong>: The launch of <strong>Brufen Duo<\/strong> added to revenues and helped strengthen Abbott\u2019s portfolio.<\/li>\n\n\n\n<li><strong>Price Flexibility<\/strong>: With the government recently deregulating non-essential medicines, Abbott can now adjust prices more freely. This has boosted margins, especially in nutritional products.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Dividend for shareholders<\/h2>\n\n\n\n<p>Abbott is also rewarding its investors. The company is expected to announce a <strong>dividend of PKR 11 per share<\/strong>, in line with its historical payout pattern.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Outlook<\/h2>\n\n\n\n<p>With strong brands, new product launches, and more control over pricing, Abbott is well-positioned to keep growing. Lower raw material prices for key ingredients (like Azithromycin and Amoxicillin) are also expected to support profitability.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Why does it matter?<\/h2>\n\n\n\n<p>For everyday investors, this shows how changes in regulation and smart product strategies can dramatically boost a company\u2019s bottom line. Abbott\u2019s growth story is not just about medicines but also about adapting to new market opportunities quickly.<\/p>\n\n\n\n<p><strong>Source: Optimus Capital Management<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Abbott Laboratories (Pakistan) Limited (ABOT) has emerged as one of the standout players in the pharmaceutical sector this year. The company\u2019s performance in the April\u2013June 2025 quarter shows how changing regulations and strong product demand are fueling growth.<\/p>\n","protected":false},"author":9252,"featured_media":6421,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[154,138],"tags":[380],"class_list":["post-11351","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-analysis","category-financials","tag-abot"],"featured_image_src":{"landsacpe":["https:\/\/ksestocks.com\/blog\/wp-content\/uploads\/2024\/11\/ABOT-STOCK-PSX-1140x445.png",1140,445,true],"list":["https:\/\/ksestocks.com\/blog\/wp-content\/uploads\/2024\/11\/ABOT-STOCK-PSX-463x348.png",463,348,true],"medium":["https:\/\/ksestocks.com\/blog\/wp-content\/uploads\/2024\/11\/ABOT-STOCK-PSX-300x188.png",300,188,true],"full":["https:\/\/ksestocks.com\/blog\/wp-content\/uploads\/2024\/11\/ABOT-STOCK-PSX.png",1920,1200,false]},"_links":{"self":[{"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/posts\/11351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/users\/9252"}],"replies":[{"embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/comments?post=11351"}],"version-history":[{"count":1,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/posts\/11351\/revisions"}],"predecessor-version":[{"id":11354,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/posts\/11351\/revisions\/11354"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/media\/6421"}],"wp:attachment":[{"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/media?parent=11351"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/categories?post=11351"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/tags?post=11351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}